Economical value of vaccines for the developing countries--the case of Instituto Butantan, a public institution in Brazil

• Published in: PLoS neglected tropical diseases Vol. 5; no. 11; p. e1300
• Main Authors: Ho, Paulo Lee, Miyaji, Eliane Namie, Oliveira, Maria Leonor Sarno, Dias, Waldely de Oliveira, Kubrusly, Flavia Saldanha, Tanizaki, Martha Massako, Martins, Elizabeth Angélica Leme, Raw, Isaias
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 01.11.2011; Public Library of Science (PLoS)
• Subjects: Agreements; Brazil - epidemiology; Care and treatment; Communicable Diseases - epidemiology; Developing Countries; Hepatitis B; Humans; Immunization; LDCs; Medicine; Policy Platform; Science Policy; Technology transfer; Vaccination; Vaccination - economics; Vaccination - methods; Vaccines; Vaccines - economics; Vaccines - supply & distribution; Brazil; Brazil; Developing Countries; Vaccines; Communicable Diseases; Humans; Vaccination
• ISSN: 1935-2735; 1935-2727; 1935-2735
• DOI: 10.1371/journal.pntd.0001300

  The companies are understandably reluctant to create competitors with knowledge and capabilities in the most up-to-date production methods and most advanced vaccines. [...]the developing country partner may obtain out-of-date technology for older vaccines. Besides this, a federal regulatory agency (ANVISA) was created that certifies the production laboratories and promotes a move to full compliance with WHO GMP guidance, a process that is not instantaneous but depends on investments that the MH began to make available starting in 1985. [...]the country should ensure the capability to undertake rigorous epidemiological studies to guide and evaluate the delivery of vaccination services.